LUTS and Sexual Dysfunction: What is the Link and How Can it Be Managed?

European Urology, Supplements

Volumn 5, Issue 12, 2006, Pages 722-728

  Heaton, Jeremy P W ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Benign prostatic hyperplasia; Lower urinary tract symptoms; Sexual dysfunction

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DUTASTERIDE; FINASTERIDE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN;

AGING; ATHEROSCLEROSIS; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; EJACULATION DISORDER; ERECTILE DYSFUNCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; LIBIDO DISORDER; LOWER URINARY TRACT SYMPTOM; PAIN; PATIENT ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATECTOMY; RETROGRADE EJACULATION; REVIEW; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SMOKING; STATISTICAL ANALYSIS; TRANSURETHRAL MICROWAVE THERMOTHERAPY; TRANSURETHRAL NEEDLE ABLATION; TRANSURETHRAL RESECTION; URETHRA DISEASE;

EID: 33746774630     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2006.06.011     Document Type: Review

References (50)

1. Panser L.A., Rhodes T., Girman C.J., et al. Sexual function of men ages 40 to 79 years: the Olmsted County Study of Urinary Symptoms and Health Status Among Men. J Am Geriatr Soc 43 (1995) 1107-1111
2. Derogatis L.R. The Derogatis Interview for Sexual Functioning (DISF/DISF-SR): an introductory report. J Sex Marital Ther 23 (1997) 291-304
3. Clayton A.H., McGarvey E.L., and Clavet G.J. The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity. Psychopharmacol Bull 33 (1997) 731-745
4. Clayton A.H., McGarvey E.L., Clavet G.J., and Piazza L. Comparison of sexual functioning in clinical and nonclinical populations using the Changes in Sexual Functioning Questionnaire (CSFQ). Psychopharmacol Bull 33 (1997) 747-753
5. Keller A., McGarvey E.L., and Clayton A.H. Reliability and construct validity of the Changes in Sexual Functioning Questionnaire Short-Form (CSFQ-14). J Sex Marital Ther 32 (2006) 43-52
6. Braun M., Wassmer G., Klotz T., et al. Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. Int J Impot Res 12 (2000) 305-311
7. Feldman H.A., Goldstein I., Hatzichristou D.G., Krane R.J., and McKinlay J.B. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 151 (1994) 54-61
8. Laumann E.O., Paik A., and Rosen R.C. Sexual dysfunction in the United States: prevalence and predictors. JAMA 281 (1999) 537-544
9. Roberts R.O., Rhodes T., Panser L.A., et al. Natural history of prostatism: worry and embarrassment from urinary symptoms and health care-seeking behavior. Urology 43 (1994) 621-628
10. Chute C.G., Panser L.A., Girman C.J., et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 150 (1993) 85-89
11. Sarma A.V., Jacobson D.J., McGree M.E., et al. A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997. J Urol 173 (2005) 2048-2053
12. Arrighi H.M., Metter E.J., Guess H.A., and Fozzard J.L. Natural history of benign prostatic hyperplasia and risk of prostatectomy. The Baltimore Longitudinal Study of Aging. Urology 38 Suppl 1 (1991) 4-8
13. Macfarlane G.J., Botto H., Sagnier P.P., et al. The relationship between sexual life and urinary condition in the French community. J Clin Epidemiol 49 (1996) 1171-1176
14. Abrams P., Donovan J.L., de la Rosette J.J., and Schafer W. International Continence Society "Benign Prostatic Hyperplasia" Study: background, aims, and methodology. Neurourol Urodyn 16 (1997) 79-91
15. Frankel S.J., Donovan J.L., Peters T.I., et al. Sexual dysfunction in men with lower urinary tract symptoms. J Clin Epidemiol 51 (1998) 677-685
16. Marberger M, Gomella L, Montorsi F, Rittmaster R, Tammela T. Sexual function and its correlation with serum testosterone and lower urinary tract symptom severity-baseline data from the REDUCE trial. Abstract presented at the International Consultation on Prostatic Diseases, Paris, France, 24-27 June 2005.
17. Vallancien G., Emberton M., Harving N., and van Moorselaar R.J. Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. J Urol 169 (2003) 2257-2261
18. Hoesl C.E., Woll E.M., Burkart M., and Altwein J.E. Erectile dysfunction (ED) is prevalent, bothersome and underdiagnosed in patients consulting urologists for benign prostatic syndrome (BPS). Eur Urol 47 (2005) 511-517
19. Blanker M.H., Bohnen A.M., Groeneveld F.P., et al. Correlates for erectile and ejaculatory dysfunction in older Dutch men: a community-based study. J Am Geriatr Soc 49 (2001) 436-442
20. Ponholzer A., Temml C., Mock K., et al. Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire. Eur Urol 47 (2005) 80-86
21. Rosen R., Altwein J., Boyle P., et al. Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7). Eur Urol 44 (2003) 637-649
22. McVary K.T., Foster H., Kusek J., Ramsdell J., and Bautista O. Self-reported sexual function in men with symptoms of BPH-a MTOPS study report. Int J Impot Res 14 (2002) ACP1.32
23. Girman C.J., Jacobsen S.J., Rhodes T., et al. Association of health-related quality of life and benign prostatic enlargement. Eur Urol 35 (1999) 277-284
24. Paick S.H., Meehan A., Lee M., Penson D.F., and Wessells H. The relationship among lower urinary tract symptoms, prostate specific antigen and erectile dysfunction in men with benign prostatic hyperplasia: results from the Proscar long-term efficacy and safety study. J Urol 173 (2005) 903-907
25. McVary K.T. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 47 (2005) 838-845
26. Bloch W., Klotz T., Loch C., et al. Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide. Prostate 33 (1997) 1-8
27. Luo J., Dunn T., Ewing C., et al. Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis. Prostate 51 (2002) 189-200
28. Crone J.K., Burnett A.L., Chamness S.L., Strandberg J.D., and Chang T.S. Neuronal nitric oxide synthase in the canine prostate: aging, sex steroid, and pathology correlations. J Androl 19 (1998) 358-364
29. Sairam K., Kulinskaya E., McNicholas T.A., Boustead G.B., and Hanbury D.C. Sildenafil influences lower urinary tract symptoms. BJU Int 90 (2002) 836-839
30. Andersson K.E., Chapple C.R., and Hofner K. Future drugs for the treatment of benign prostatic hyperplasia. World J Urol 19 (2002) 436-442
31. McVary K.T., Razzaq A., Lee C., et al. Growth of the rat prostate gland is facilitated by the autonomic nervous system. Biol Reprod 51 (1994) 99-107
32. Golomb E., Rosenzweig N., Eilam R., and Abramovici A. Spontaneous hyperplasia of the ventral lobe of the prostate in aging genetically hypertensive rats. J Androl 21 (2000) 58-64
33. McVary K.T., Rademaker A., Lloyd G.L., and Gann P. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 174 (2005) 1327-1433
34. Tarcan T., Azadzoi K.M., Siroky M.B., Goldstein I., and Krane R.J. Age-related erectile and voiding dysfunction: the role of arterial insufficiency. Br J Urol 82 (1998) 26-33
35. Brading A., Pessina F., Esposito L., and Symes S. Effects of metabolic stress and ischaemia on the bladder, and the relationship with bladder overactivity. Scand J Urol Nephrol Suppl 215 (2004) 84-92
36. Galvin D.J., Watson R.W., O'Neill A., et al. Hypoxia inhibits human bladder smooth muscle cell proliferation: a potential mechanism of bladder dysfunction. Neurourol Urodyn 23 (2004) 342-348
37. Gacci M., Bartoletti R., Figlioli S., et al. Urinary symptoms, quality of life and sexual function in patients with benign prostatic hypertrophy before and after prostatectomy: a prospective study. BJU Int 91 (2003) 196-200
38. Brookes S.T., Donovan J.L., Peters T.J., Abrams P., and Neal D.E. Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomised controlled trial. BMJ 324 (2002) 1059-1061
39. Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology 51 (1998) 901-906
40. Schulman C.C., Cortvriend J., Jonas U., et al. Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. Eur Urol 36 (1999) 609-620
41. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 51 (1998) 892-900
42. Chapple C.R., Wyndaele J.J., Nordling J., et al. Tamsulosin, the first prostate-selective alpha1A-adrenoceptor antagonist: a meta-analysis of two randomised, placebo-controlled, mulitcentre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 29 (1996) 155-167
43. van Moorselaar R.J., Hartung R., Emberton M., et al. Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. BJU Int 95 (2005) 603-608
44. McConnell J.D., Bruskewitz R., Walsh P.C., et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 338 (1998) 557-563
45. McConnell J.D., Roehrborn C.G., Bautista O.M., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2387-2398
46. Roehrborn C.G., Boyle P., Nickel J.C., Hoefner K., and Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60 (2002) 434-441
47. Debruyne F., Barkin J., van Erps P., et al. Efficacy and safety of long-term treatment with the dual 5α-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 46 (2004) 488-495
48. Debruyne F.M., Jardin A., Colloi D., et al. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur Urol 34 (1998) 169-175
49. Jardin A., Debruyne F., and McCarthy C. Sexual function in men with BPH treated either with an alpha adrenergic blocker alfuzosin or the 5-alpha reductase inhibitor finasteride or the combination. J Urol 159 (1998) 331A
50. Leliefeld H.H., Stoevelaar H.J., and McDonnell J. Sexual function before and after various treatments for symptomatic benign prostatic hyperplasia. BJU Int 89 (2002) 208-213